Mass Tort & MDL Procedure Glossary

A 524(g) trust is a settlement trust established under 11 U.S.C. § 524(g) through a company's Chapter 11 bankruptcy reorganization, designed to channel all present and future mass tort liability — historically asbestos claims, and more recently other latent-injury products — into a single trust that assumes the debtor's liability in exchange for an injunction permanently channeling all related claims away from the reorganized company and its affiliates. Confirmation of a 524(g) plan requires, among other conditions, approval by at least 75% of voting claimants and appointment of a future claimants' representative to protect individuals who have been exposed but not yet manifested injury, reflecting the latency periods characteristic of asbestos and similar disease-based mass torts. Once established, a 524(g) trust operates independently of the bankruptcy court going forward, applying its own trust distribution procedures — often a grid-like schedule of disease categories and payment percentages — to process claims for decades after the underlying bankruptcy has closed. Because the channeling injunction extinguishes claims against the reorganized debtor and often against affiliated non-debtor parties who contribute funding to the trust, 524(g) resolution fundamentally changes the litigation landscape by converting an adversarial liability determination into an administrative claims process against a fixed trust corpus. More →

An attorney lien in the mass tort context is the statutory or common-law right of a plaintiff's attorney to be paid contingency fees and reimbursed advanced case costs directly out of the client's settlement or verdict proceeds before any funds are disbursed to the client, arising under state law that varies in form between a charging lien against the specific recovery and a broader retaining lien over client files and property in the attorney's possession. In mass tort settlements administered through a claims facility, attorney liens are typically satisfied automatically as part of the distribution waterfall, with the fee percentage and cost reimbursement calculated and deducted before the net amount reaches the claimant, and disputes over fee entitlement — most commonly arising from referral arrangements, mid-case attorney substitutions, or co-counsel splits — are resolved separately from the underlying settlement distribution, often through interpleader or a dedicated fee dispute process. Because the attorney lien attaches to the specific recovery and generally has priority over unsecured claims against the same proceeds, it interacts directly with any litigation financing arrangement the attorney or client has entered, and funding agreements must expressly address the relative priority between the funder's repayment right and the attorney's fee lien. More →

Case inventory management refers to the operational systems and processes a mass tort law firm uses to track, organize, and progress a large volume of individual client matters simultaneously — including client intake and retention documentation, medical records collection and organization, fact sheet drafting and submission, deadline and statute of limitations tracking, and ongoing client communication — across what can be a docket of many thousands of individual cases. Because mass tort litigation is fundamentally a volume business in which a firm's economics depend on efficiently managing large numbers of individually smaller-value claims rather than intensively litigating a single matter, the quality of a firm's case management infrastructure — its case management software, staffing ratios of paralegals and case managers to attorneys, and records collection processes — has a direct and measurable effect on outcomes such as fact sheet compliance rates, client retention, and the firm's ability to respond to court deadlines across the full inventory. Firms that scale client intake faster than their case management infrastructure frequently experience elevated attrition, missed deadlines, and deficiency notices, problems that surface publicly through the deficiency and show cause process. Because this operational layer is rarely visible from the outside absent litigation of these downstream compliance failures, evaluating it typically requires direct diligence into a firm's internal systems and staffing. More →

A Case Management Order (CMO) is any of the sequential orders a transferee judge issues under Federal Rule of Civil Procedure 16 to govern the procedural conduct of an MDL, addressing matters such as pleading deadlines, discovery protocols, expert disclosure schedules, fact sheet and census requirements, bellwether selection procedures, and Daubert briefing schedules. Unlike a single governing document, CMOs in a large MDL accumulate over the docket's life — often numbering in the dozens — with each addressing a discrete procedural question as it arises, sometimes amending or superseding prior orders. Because MDL consolidation centralizes pretrial management before a single judge with broad case management discretion, CMOs collectively function as the operative rulebook for the entire docket, and a transferee judge's approach to them — aggressive versus deliberate, prescriptive versus flexible — signals the pace and rigor with which the litigation will proceed. Counsel on both sides negotiate proposed CMO language extensively, since procedural terms embedded in an early CMO, such as the scope of permissible discovery or the standard for fact sheet compliance, can materially shape downstream litigation and settlement leverage long before any merits ruling is made. More →

A census order, sometimes called a registration order, is a case management order requiring every law firm with potential claims related to the MDL's subject matter — including claims not yet formally filed — to register basic identifying and claim information with the court or a court-approved claims administrator by a specified deadline. Unlike a short-form complaint, which formally commences an individual lawsuit, a census registration is often a lower-burden, non-adversarial data collection exercise designed to give the transferee court, the parties, and any eventual settlement administrator an accurate count of the total universe of potential claims — including unfiled claims held by counsel pending investigation — well before every claimant has actually filed suit. Census orders have become increasingly common in settlement-oriented MDLs, because an accurate claim count is a prerequisite to structuring an aggregate settlement fund, negotiating a global resolution, and calculating the enrollment percentage needed to satisfy a defendant's participation threshold. Some census orders carry consequences for non-compliance, including preclusion from participating in an eventual settlement, which gives firms a strong incentive to register even claims still in the investigation or pre-suit stage. More →

A co-counsel and referral fee agreement is a contract between two or more law firms governing the division of contingency fees earned from a shared mass tort client or block of clients, typically arising when a referring firm — often one with strong marketing and intake capability but limited MDL litigation experience — sends cases to a lead or trial-capable firm in exchange for a percentage of any resulting fee, or when multiple firms jointly handle a matter and agree in advance how to split the eventual recovery. These agreements must generally comply with state bar ethics rules governing fee division between lawyers not in the same firm, which typically require client consent to the arrangement, a division proportional to services rendered or joint responsibility assumed, and a fee that remains reasonable in the aggregate. In the mass tort context, co-counsel arrangements are central to how large dockets are actually staffed: intake-focused firms generate substantial claim volume through advertising and client acquisition but frequently lack the litigation infrastructure to serve on a PSC or try bellwether cases, while trial-capable firms depend on referral relationships to build the case inventory needed to justify their common benefit investment. Disputes over referral fee entitlement, particularly following late-stage client transfers, are a recurring source of litigation collateral to the underlying mass tort itself. More →

Common issues versus individual issues bifurcation is a trial management technique, available to transferee courts under Federal Rule of Civil Procedure 42(b), in which a mass tort trial is divided into separate phases that first resolve questions common to some or all plaintiffs — such as general causation, whether the defendant's conduct was negligent or the product defective, or whether punitive conduct occurred — before proceeding to a second phase addressing questions that vary by individual plaintiff, such as specific causation and compensatory damages. Bifurcation is intended to promote efficiency by resolving docket-wide questions once rather than relitigating identical evidence in every individual trial, and a common-issues verdict favorable to plaintiffs can then be applied, subject to issue preclusion principles, across some or all of the remaining individual cases without requiring the common evidence to be retried. Bifurcation is not without controversy: defendants frequently argue that separating liability-related common issues from individual causation and damages issues risks juror confusion and can prejudice the defense by allowing a punitive or liability finding to be reached in the abstract. Some jurisdictions and some transferee judges decline to bifurcate mass tort trials for these reasons, preferring instead to try each bellwether case as a complete, self-contained proceeding. More →

Daubert gatekeeping refers to the trial court's obligation under Federal Rule of Evidence 702 and the Supreme Court's decisions in Daubert v. Merrell Dow Pharmaceuticals (1993), General Electric Co. v. Joiner (1997), and Kumho Tire Co. v. Carmichael (1999) to screen expert testimony for reliability before it reaches a jury, assessing whether the expert's methodology is scientifically valid and reliably applied to the facts of the case. In mass tort MDLs, gatekeeping is typically exercised through a single, consolidated hearing addressing the admissibility of the plaintiffs' — and sometimes the defendants' — general causation experts, since the same expert opinions and methodology apply across every claim on the docket. A transferee judge's Daubert ruling is reviewed only for abuse of discretion on appeal, giving trial courts substantial latitude, and outcomes can range from full admission, to partial exclusion of specific opinions or methodologies, to wholesale exclusion that ends the docket. Because gatekeeping hearings often follow an earlier, non-evidentiary science day presentation, the transferee judge typically enters the Daubert phase with an informed view of the scientific dispute, and the eventual ruling is shaped as much by the judge's accumulated impression of the science as by the formal briefing on any single motion. More →

A Direct Filing Order is a case management order entered by an MDL transferee court, pursuant to its authority under 28 U.S.C. § 1407 and Federal Rule of Civil Procedure 16, permitting plaintiffs to file new lawsuits directly in the transferee court rather than filing in a district with proper venue and waiting for the Judicial Panel on Multidistrict Litigation to issue a conditional transfer order. Without a direct filing order, every new plaintiff must file where venue and jurisdiction exist and then wait for transfer, a process that can take months and fragments the docket across the country in the interim. Direct filing orders typically preserve each plaintiff's home-state substantive law and choice-of-law rights notwithstanding the filing location, and many pair with a tolling agreement or savings clause protecting claimants who might otherwise face a statute-of-limitations problem while the order is negotiated. Not every transferee court enters one, and terms vary — some limit direct filing to specific case types or require a companion registration step. The order functions as case-intake infrastructure: it determines how quickly a mass tort docket can scale from an initial handful of cases to the thousands of individual claims that make MDL consolidation economically viable in the first place. More →

A discovery pool is a defined subset of plaintiffs in an MDL — larger than the small group ultimately selected as bellwether trial candidates but smaller than the full docket — subjected to full, individualized fact discovery, including depositions, medical record production, and expert case-specific reports, for the purpose of developing a representative sample of claim types, injury severities, and factual circumstances before bellwether selection narrows the pool further. Discovery pool selection is typically negotiated between the PSC and defense counsel and approved by the transferee court through a case management order specifying the pool size and the criteria — often a mix of plaintiff picks, defense picks, and random or stratified selection — used to assemble a sample that fairly represents the docket's overall composition rather than only its strongest or weakest claims. Because full individualized discovery is expensive and time-consuming, conducting it against a discovery pool rather than the entire docket allows the parties and the court to develop the factual record needed to assess claim value and select bellwether candidates without incurring the cost of full discovery against every claim, a cost that would be prohibitive across dockets numbering in the thousands. The results of discovery pool development, including any patterns in claim strength that emerge across the sample, often inform both bellwether selection and the eventual design of a settlement grid's compensation criteria. More →

An extraordinary injury fund is a supplemental compensation pool established within a mass tort global settlement to provide additional payments to claimants whose injuries or circumstances fall outside the range the standard settlement grid was designed to compensate — for example, unusually severe complications, injuries to minors, wrongful death with dependent children, or documented case-specific facts that a special master or claims administrator determines warrant compensation above the grid's default tier for that injury category. Because a settlement grid necessarily compresses a wide range of individual circumstances into a limited number of standardized tiers to enable efficient administration across a large claimant population, an extraordinary injury fund functions as a release valve for the small subset of claims where the grid's standardized approach would produce a result plaintiffs' counsel and the claims administrator agree is clearly inadequate. Access to the fund typically requires a separate application and review process, often before a special master, with claimants bearing the burden of demonstrating why their case falls outside the grid's normal parameters, and the fund itself is usually capped at a fixed aggregate amount set during settlement negotiations rather than being open-ended. Because the fund draws from a fixed pool, allocation to one claimant's application necessarily reduces the amount available for others. More →

The fact sheet deficiency and dismissal process is the enforcement mechanism transferee courts use to police compliance with plaintiff fact sheet requirements, typically structured as a tiered sequence in which a claims administrator or defense counsel flags an incomplete or non-responsive submission, plaintiff's counsel receives a defined cure period specified in the applicable case management order to correct the deficiency, and continued non-compliance results in placement on a show cause list and, absent an adequate response, dismissal of the claim with or without prejudice. Deficiency categories commonly include missing medical authorizations, unsigned verifications, absent exposure documentation, and unresponsive answers to material questions such as prior diagnoses or competing exposures. Because fact sheet compliance obligations fall on plaintiffs' counsel rather than on the court, the deficiency process functions as an ongoing audit of a law firm's case management infrastructure — firms with strong client communication systems and organized medical records intake clear deficiencies quickly, while firms with high client attrition or thin staffing accumulate deficiency notices that compound over successive rounds. Transferee courts periodically enter omnibus dismissal orders disposing of hundreds or thousands of chronically deficient claims in a single ruling, which can materially and abruptly reduce the size of a docket. More →

Federal preemption in pharmaceutical and medical device mass torts is the doctrine, grounded in the Supremacy Clause, under which federal regulatory requirements displace state-law tort claims that would impose additional or conflicting obligations on a manufacturer. The doctrine operates differently across product categories: for medical devices that received premarket approval from the FDA, Riegel v. Medtronic (2008) held that state-law claims imposing requirements different from or in addition to federal requirements are expressly preempted under 21 U.S.C. § 360k; for brand-name prescription drugs, Wyeth v. Levine (2009) held that state-law failure-to-warn claims are generally not preempted because federal law permits manufacturers to unilaterally strengthen a warning label without prior FDA approval through the changes-being-effected process; and for generic drugs, PLIVA v. Mensing (2011) held that failure-to-warn claims are preempted because federal law requires generic labeling to match the brand label exactly. A separate implied preemption doctrine under Buckman Co. v. Plaintiffs' Legal Committee (2001) bars state-law claims premised on an alleged fraud on the FDA, reasoning that policing the integrity of FDA submissions is a matter exclusively for federal enforcement. Preemption exposure therefore varies dramatically depending on whether the product is a premarket-approved device, a brand drug, or a generic drug. More →

General causation is the threshold scientific question in a toxic tort or pharmaceutical mass tort of whether the product or substance at issue is capable of causing the type of injury the plaintiffs allege, established through epidemiological studies, toxicological data, biological mechanism evidence, and expert analysis applying an accepted methodology such as the Bradford Hill criteria. General causation is litigated docket-wide rather than claim by claim, because the scientific question — can this drug cause this cancer, can this chemical cause this disease — does not vary from plaintiff to plaintiff, which is why MDL transferee courts typically resolve it through a single, consolidated Daubert proceeding applicable to the entire docket. A ruling excluding the plaintiffs' general causation experts is frequently case-dispositive for the entire MDL, because without admissible evidence that the product can cause the alleged injury at all, no individual plaintiff can proceed to prove that it did cause their specific injury. Conversely, admission of plaintiffs' general causation experts under Daubert v. Merrell Dow Pharmaceuticals and Federal Rule of Evidence 702 is typically the single most significant valuation event in a mass tort docket's life, since it validates the scientific premise underlying every claim on file. More →

A holdback escrow is a reserve withheld from an individual plaintiff's settlement or verdict proceeds at the point of initial distribution, pending resolution of amounts that cannot yet be finally determined — commonly outstanding medical liens, Medicare conditional payment demands, disputed common benefit assessments, or contested attorney fee or referral splits among co-counsel. Because lien resolution and common benefit fee allocation frequently take many months to finalize even after a settlement fund has been established and a claimant's individual payment tier assigned, plaintiffs' counsel and claims administrators routinely distribute the undisputed portion of a claimant's net recovery promptly while holding back a calculated reserve sufficient to cover the maximum reasonably anticipated lien or fee exposure. Once the underlying dispute is resolved, the holdback is released according to the final determination — paid out to the lienholder, distributed among co-counsel, or returned to the claimant if the actual liability came in below the reserved amount. Holdback percentages are typically set conservatively to protect against under-reserving, since a shortfall discovered after full distribution creates disproportionate collection difficulty compared to releasing an over-reserved amount once the true liability is known. More →

A holdout defendant is a defendant in a multi-defendant mass tort docket that declines to participate in a global settlement reached by some or all of its co-defendants, choosing instead to continue litigating the claims against it individually, whether because it disputes liability more strongly than its co-defendants, believes its market share or exposure period gives it a stronger defense, has greater financial capacity to withstand continued litigation, or calculates that remaining claims against it will be weaker once co-defendants have exited the docket. Holdout status can shift materially over the life of a docket — a defendant that declines an early settlement opportunity may face increasing pressure to settle as bellwether verdicts accumulate against it specifically, or conversely may gain leverage if the remaining claim pool concentrated against it turns out to have weaker product identification or causation profiles once co-defendants' better-documented claims have been resolved. In multi-defendant dockets, plaintiffs' counsel and the transferee court both have an interest in avoiding permanent holdout status, since claims against a defendant that never settles must eventually proceed to individual trial or be tried through the bellwether and remand process, which is materially slower and less certain than negotiated resolution. More →

An inactive docket, sometimes called a deferred or administrative docket, is a case management mechanism used in some MDLs to hold claims that have been filed to preserve the claimant's rights against an applicable statute of limitations but that are not yet ripe for active litigation — most commonly because the claimant has been exposed to the product at issue but has not yet been diagnosed with a qualifying injury, or because a diagnosis exists but does not yet meet a minimum severity or type threshold the docket is currently litigating. Placement on an inactive docket removes the claim from active case management deadlines such as fact sheet submission and census requirements while preserving the claim's filing date and its place in the MDL, with the case management order typically specifying the trigger — such as a subsequent diagnosis — that would move the claim onto the active docket for full litigation. Inactive dockets are particularly common in mass torts involving screening-detected conditions or long latency periods, where large numbers of exposed individuals may never develop a compensable injury, and requiring every exposed person to actively litigate immediately would overwhelm the court and the parties with claims that may never mature into a genuine dispute. Some inactive docket orders impose periodic status reporting or reactivation deadlines to prevent claims from remaining indefinitely dormant. More →

Innovator liability is a theory of tort liability under which a brand-name pharmaceutical manufacturer may be held liable for injuries caused by a generic version of its drug, on the theory that the brand manufacturer authored the warning label that both the brand and generic products are required to use, and that its negligent failure to update or adequately warn extends to patients who took the generic equivalent. The theory emerged from the tension created by PLIVA, Inc. v. Mensing (2011), in which the Supreme Court held that generic manufacturers cannot be sued for failure-to-warn claims because federal law requires generic labeling to match the brand-name label exactly, leaving generic-drug patients with no viable failure-to-warn remedy against the entity that actually manufactured the product they took. Innovator liability, first recognized by the California Court of Appeal in Conte v. Wyeth (2008), attempts to close this gap by allowing the injured generic-drug patient to sue the brand manufacturer instead. The overwhelming majority of state courts to consider the theory have rejected it, reasoning that liability should not extend to a defendant that never manufactured, sold, or profited from the product the plaintiff actually used, making it a minority and jurisdiction-specific theory rather than a generally available cause of action. More →

The Judicial Panel on Multidistrict Litigation (JPML) is a special panel of federal judges authorized under 28 U.S.C. § 1407 to determine whether civil actions pending in different federal districts share common questions of fact warranting consolidation, to select the transferee district and judge, and to issue conditional transfer orders bringing newly filed or discovered related cases into an existing MDL as they arise. The Panel's transfer authority is limited to coordinating pretrial proceedings — it does not have the power to consolidate cases for trial — and the Supreme Court's decision in Lexecon Inc. v. Milberg Weiss Bershad Hynes & Lerach (1998) confirmed that a transferee court must remand each individual case back to its originating district for trial once pretrial proceedings conclude, unless the case settles, is otherwise resolved, or the parties affirmatively consent to trial in the transferee court under 28 U.S.C. § 1404(a). In practice, the overwhelming majority of MDL cases never reach the remand stage because they resolve through global settlement, individual settlement, or dismissal while still before the transferee court, making remand for trial a comparatively rare event reserved for bellwether cases and any claims that survive the settlement process without resolving. The JPML also has authority to remand an entire MDL when it determines that continued centralization no longer serves the convenience of the parties. More →

The latency period is the interval between exposure to a harmful product or substance and the manifestation of a diagnosable injury or disease, which in mass tort litigation involving chronic disease — asbestos-related mesothelioma, certain cancers linked to chemical or pharmaceutical exposure, and similar disease processes — can extend anywhere from several years to several decades. Long latency periods create distinctive litigation and financing dynamics not present in acute-injury torts: claimants may not know they have a viable claim until long after exposure and after evidence, witnesses, and corporate records relevant to establishing exposure and causation have degraded or disappeared. Latency also interacts directly with statute of limitations analysis, since most jurisdictions apply a discovery rule that tolls the limitations period until the plaintiff knew or reasonably should have known of the injury and its connection to the defendant's conduct — a rule that becomes essential to claim viability precisely because latency can otherwise place claim accrual decades after the underlying exposure. Mass torts with long latency periods also tend to generate rolling waves of new claims over extended periods, as successive cohorts of exposed individuals are diagnosed years or decades apart. More →

The learned intermediary doctrine holds that a pharmaceutical or medical device manufacturer satisfies its duty to warn end users of a product's risks by providing an adequate warning to the prescribing physician, rather than directly to the patient, on the theory that the physician evaluates the product's risks and benefits for the specific patient and translates that information into an individualized treatment decision. The doctrine is recognized in some form in nearly every U.S. jurisdiction for prescription products, and it functions as a central causation-adjacent defense in pharmaceutical and medical device mass torts: even where a plaintiff can show the manufacturer's warning was inadequate, the claim fails unless the plaintiff can also show that an adequate warning would have changed the prescribing physician's decision to prescribe or the patient's decision to take the product. A minority of jurisdictions recognize exceptions, most notably for direct-to-consumer advertised drugs, reasoning that the manufacturer's marketing bypasses the intermediary function the doctrine assumes. Defendants in pharmaceutical mass torts routinely depose prescribing physicians specifically to establish that the physician was independently aware of the risk at issue or would have prescribed the product regardless of any additional warning, directly attacking the causal link the doctrine requires plaintiffs to prove. More →

Liaison counsel is a court-appointed role in an MDL, typically filled by an attorney based in the transferee district, responsible for administrative and logistical functions such as maintaining the master service list, coordinating filing and communication between the parties and the court, managing the shared document repository, and facilitating scheduling — functions distinct from the substantive litigation strategy, discovery direction, and settlement negotiation authority held by the Plaintiff Steering Committee and lead counsel. Because liaison counsel's role is administrative rather than strategic, compensation for this work is typically modest relative to PSC and lead counsel common benefit awards, and the position is sometimes held by a smaller local firm that would not otherwise have the resources or client volume to serve on the PSC itself. Some MDLs separate plaintiffs' liaison counsel from defense liaison counsel, each performing parallel administrative functions for their respective sides, while the leadership and strategic decision-making on each side remains with the PSC or the defense trial team. The role is a useful entry point for a smaller local firm to gain visibility and standing within a large MDL's leadership structure, occasionally serving as a stepping stone to a more substantive PSC appointment in the same or a future docket. More →

A Lone Pine order is a case management order, named for the New Jersey trial court decision in Lore v. Lone Pine Corp. (1986), requiring plaintiffs in a mass tort docket to make a threshold evidentiary showing — typically an expert report or sworn statement establishing exposure, injury, and a causal link to the defendant's product — before the case may proceed further, often before full merits discovery begins. Defendants favor Lone Pine orders as an early screening mechanism to identify and dismiss weak or unsupportable claims filed to hold a place on the docket without a genuine evidentiary basis, a pattern common in dockets built through mass advertising and rapid intake. Plaintiffs' counsel typically oppose them as an improper attempt to impose a summary-judgment-level burden before discovery has occurred, and courts are divided on their propriety — some transferee judges decline to enter them at all as inconsistent with normal pretrial sequencing, while others use narrower versions limited to specific red-flag categories of claims. Where entered, a Lone Pine order can dismiss a substantial share of a docket's weakest claims in a single event, materially reshaping the size and composition of the remaining plaintiff pool. More →

A Master Complaint is a single, comprehensive pleading filed in an MDL that sets out the common factual allegations, legal theories, and causes of action applicable across the consolidated docket, serving as a template that individual plaintiffs adopt rather than each drafting a full complaint from scratch. It is typically negotiated between the Plaintiff Steering Committee and defense counsel, or drafted by the PSC and subjected to a motion to dismiss testing the viability of the docket's core legal theories before any individual case proceeds further. Because a ruling on the master complaint's sufficiency — for example, on a preemption or learned intermediary defense raised at the pleading stage — applies to every plaintiff who has adopted it, the master complaint functions as an efficient, docket-wide test of legal viability analogous to how general causation testing functions for the scientific theory. Individual plaintiffs typically join it by filing a short-form complaint incorporating its allegations by reference and adding only plaintiff-specific facts, avoiding the need to replead every common allegation in every individual case. A successful motion to dismiss the master complaint can eliminate an entire legal theory or defendant across the whole docket in a single ruling, making the pleading-stage battle over it a significant early inflection point. More →

Opt-out rights in a negotiated mass tort settlement refer to an individual claimant's contractual right to decline participation in a global settlement and instead pursue an individual claim through continued litigation, a right that exists in mass tort settlements as a matter of contract rather than as the default rule that governs class action settlements under Rule 23. Because mass tort claimants are individual parties to individual lawsuits rather than absent members of a certified class, no claimant is automatically bound by a negotiated global settlement unless that claimant's own counsel affirmatively enrolls the claim, which means opt-out in the mass tort context functions in the opposite direction from class action opt-out — participation is the affirmative choice, not the default. Settlement agreements typically require a minimum enrollment percentage to become effective at all, meaning that a critical mass of individual opt-in decisions is a condition precedent to the settlement functioning, rather than a mechanism for a small minority to break away from an otherwise binding resolution. Claimants who decline to enroll retain their individual claims and bear the risk and potential upside of continued litigation, including exposure to any subsequent adverse ruling that would have been avoided by accepting the settlement's guaranteed grid payment. More →

The product identification defense is a challenge asserted by a defendant in a mass tort case — most commonly in asbestos, talc, and other multi-manufacturer chemical exposure litigation — arguing that the plaintiff cannot prove exposure to that specific defendant's product, as distinguished from a similar product made by one of several other manufacturers who supplied the same industry, worksite, or product category during the relevant exposure period. Product identification is a distinct and often more fundamental hurdle than general or specific causation, because it fails at the threshold factual question of whether the defendant's product was present at all, before any question of whether the product caused the plaintiff's injury is reached — a problem compounded in cases involving exposures that occurred decades earlier, unbranded or commodity products, or workplaces that used products from many manufacturers interchangeably over time. Plaintiffs typically respond with co-worker testimony, purchase and supply records, employer records, and, in some jurisdictions, a substantial factor or frequency-regularity-proximity standard that allows a jury to find product identification satisfied based on evidence that the defendant's product was regularly present at the worksite during the exposure period, even without direct proof the plaintiff personally handled it. Some jurisdictions have rejected looser identification standards in favor of requiring more direct proof, making the applicable standard a significant jurisdiction-specific variable. More →

Punitive damages in mass tort litigation are non-compensatory damages awarded to punish a defendant for particularly egregious conduct — such as concealing known safety risks, manipulating clinical trial data, or continuing to market a product after internal knowledge of serious harm — and to deter similar conduct going forward, awarded in addition to compensatory damages for the plaintiff's actual injury. Their availability and size are constrained by the Due Process Clause under the Supreme Court's decisions in BMW of North America v. Gore (1996) and State Farm Mutual Automobile Insurance Co. v. Campbell (2003), which established guideposts including the reprehensibility of the defendant's conduct, the disparity between the punitive award and actual harm, and comparable civil penalties, and which generally disfavor punitive-to-compensatory ratios exceeding single digits absent particularly egregious circumstances. Many states also impose statutory caps on punitive damages or require a bifurcated trial structure separating liability and compensatory phases from a subsequent punitive phase, and some states prohibit punitive damages against pharmaceutical manufacturers whose products received FDA approval absent evidence of fraud on the agency. Because punitive exposure often depends on internal corporate documents establishing knowledge and intent, its magnitude and even its availability frequently remain uncertain well into a docket's life. More →

A Short-Form Complaint is an abbreviated pleading that an individual plaintiff files to join an MDL by incorporating the master complaint's common factual and legal allegations by reference, adding only plaintiff-specific information such as the product used, dates and duration of exposure, alleged injury, and the plaintiff's residence and relevant medical history. Short-form complaints dramatically reduce the pleading burden associated with mass onboarding of individual claims, allowing a docket to scale from dozens to thousands of plaintiffs without each case requiring a full standalone complaint drafted and filed by counsel. Most MDL case management orders establish a standardized short-form template with required fields, and the transferee court typically ties filing deadlines to census or registration deadlines, using non-compliance as grounds for dismissal from the docket. Because the short-form complaint captures the minimum plaintiff-specific facts needed to establish that a claim fits within the docket's common allegations, deficiencies in a filing — such as an unclear product identification or missing exposure dates — are an early indicator of the same case-quality issues that will later surface in fact sheet compliance and specific causation proof. More →

A show cause order is a court order requiring a party — typically plaintiff's counsel on behalf of one or more claimants — to appear or file a written submission demonstrating why a specified adverse action, most commonly dismissal, should not be taken given an identified deficiency, such as chronic fact sheet non-compliance, failure to prosecute, or failure to comply with a prior case management deadline. Show cause orders function as the final procedural checkpoint before dismissal in most MDL enforcement sequences, giving plaintiffs' counsel one last defined opportunity to cure the deficiency, explain extenuating circumstances, or voluntarily dismiss the claim before the court acts unilaterally. Transferee courts frequently issue show cause orders in batches covering hundreds of claims identified through a periodic compliance audit, with a single hearing or briefing schedule resolving the fate of the entire batch. Because a show cause order sits at the intersection of docket management efficiency and individual due process — courts must balance moving a large docket forward against ensuring individual claimants are not dismissed without adequate notice — the standards courts apply to responses vary, with some transferee judges granting liberal extensions for good cause and others enforcing deadlines strictly to maintain docket discipline. More →

A special master is a neutral third party appointed by the court under Federal Rule of Civil Procedure 53 to assist with specific tasks in an MDL that exceed the court's own capacity to manage directly, most commonly discovery disputes, settlement allocation and claims administration, and common benefit fee allocation among PSC firms. Special masters are typically retired judges or senior practitioners with subject-matter or MDL-specific experience, and their fees are usually paid from a court-ordered assessment on the parties or from the common benefit fund rather than by the court itself. In the settlement context, a special master appointed to design or administer a claims grid brings a degree of perceived neutrality to allocation decisions that the PSC or defense counsel, as interested parties, cannot provide, which is often essential to obtaining buy-in from a large and heterogeneous plaintiff population for a grid's relative valuations. Special masters overseeing common benefit fee allocation perform a similarly load-bearing function, resolving what is often the most contentious dispute in any large MDL: how to divide a fee pool among dozens of contributing firms with competing claims to credit for the docket's success. More →

Specific causation is the claim-by-claim question of whether the defendant's product actually caused a particular plaintiff's injury, as distinguished from general causation's docket-wide question of whether the product is capable of causing that type of injury at all. Establishing it typically requires an individualized expert opinion — often from a treating physician or retained causation expert — that rules out alternative causes of the plaintiff's condition through a differential diagnosis or differential etiology methodology, accounts for the plaintiff's dose or duration of exposure, and applies the temporal relationship between exposure and onset of injury. Because specific causation depends on each plaintiff's individual medical history, exposure profile, and competing risk factors, it cannot be resolved docket-wide the way general causation can, and it is the central issue tried in bellwether trials once general causation has been established. It is also the primary axis along which a mass tort claim inventory varies in strength: a claimant with a clean medical history, well-documented exposure, and short latency between exposure and diagnosis presents a materially stronger case than one with confounding risk factors, competing diagnoses, or ambiguous exposure records. More →

A statute of repose is a legislatively fixed outer time limit on a defendant's liability, measured from a defined triggering event such as the date of manufacture, sale, or first use of a product, that extinguishes the right to bring a claim once the period expires regardless of when the plaintiff's injury actually occurred or was discovered. A statute of repose differs fundamentally from a statute of limitations: limitations periods are typically triggered by injury discovery and can be tolled under a discovery rule, while a repose period runs from the triggering event itself and generally cannot be tolled even if the plaintiff had no possible way of knowing about a future injury during the repose window. Whether a state recognizes a product liability repose statute at all, and what the applicable period is, is set entirely by state legislatures and varies significantly by jurisdiction, making the analysis jurisdiction-specific for every mass tort docket that spans multiple states. Repose statutes are particularly consequential in long-latency mass torts, where the gap between exposure and injury manifestation can exceed the repose period entirely, extinguishing a claim before the plaintiff was ever injured in a legally cognizable way. More →

A walk-away provision is a contractual term in a mass tort global settlement agreement granting the defendant the right to terminate or rescind the entire settlement if plaintiff enrollment falls below a negotiated participation threshold by a specified deadline, protecting the defendant from paying for global resolution while a meaningful share of claimants remain free to litigate individually. Because a global settlement's value to a defendant depends on achieving something close to complete finality, walk-away thresholds are typically set high, and settlement agreements frequently build in an enrollment period during which plaintiffs' counsel actively work to secure client sign-ons before the deadline arrives. If enrollment falls short, the defendant may have the option, rather than the obligation, to walk away, and in some negotiated structures the parties instead agree to renegotiate settlement terms — often reducing the aggregate fund or adjusting the grid — rather than allowing the entire agreement to collapse. The period immediately before a walk-away deadline is typically the most operationally intense phase of a mass tort settlement for plaintiffs' firms, since securing enrollment sign-off from thousands of individual clients within a fixed window is a significant logistical undertaking distinct from the underlying legal work. More →